| | |
MS cases
|
Control cases
|
|---|
|
Lab I.D.
|
Sex/Age (y)
|
Disease
|
MS type
| | | |
Lab ID
|
Sex/Age (y)
|
|---|
|
Duration (y)
|
Last relapse
|
Steroids (Y/N)
|
Treatment
|
|---|
|
MS 11/11
|
M/33
|
3
|
RR
|
5 mo
|
N
|
Natalizumab
|
C2/11
|
F/45
|
|
MS 16/11
|
F/33
|
1
|
RR
|
1 yr
|
N
|
Copaxone
|
C4/11
|
F/28
|
|
MS 19/11
|
F/36
|
3
|
RR
|
3 yr
|
N
|
Copaxone
|
C7/11
|
M/22
|
|
MS 24/11
|
F/32
|
12
|
RR
|
2 yr
|
N
|
Naltrexone
|
C13/11
|
M/49
|
|
MS 31/11
|
M/49
|
3
|
RR
|
1 yr
|
N
|
Natalizumab
|
C14/11
|
F/30
|
|
MS 32/11
|
F/44
|
22
|
RR
|
2.5 yr
|
N
|
Natalizumab
|
C16/11
|
F/33
|
|
MS 33/11
|
F/39
|
12
|
RR
|
1 yr
|
N
|
Natalizumab
|
C17/11
|
M/31
|
|
MS 35/11
|
F/24
|
6
|
RR
|
2 yr
|
N
|
Natalizumab
|
C23/11
|
F/82
|
|
MS 36/11
|
F/33
|
10
|
RR
|
2 yr
|
N
|
Natalizumab
|
C24/11
|
F/39
|
|
MS 38/11
|
F/46
|
13
|
RR
|
3.5 yr
|
N
|
Natalizumab
|
C2/12
|
F/24
|
|
MS 39/11
|
M/33
|
6
|
RR
|
3.5 yr
|
N
|
Natalizumab
|
C5/12
|
F/42
|
|
MS 41/11
|
M/29
|
3
|
RR
|
2 yr
|
N
|
Natalizumab
| | |
|
MS 44/11
|
F/58
|
22
|
RR/SP
|
NK
|
N
|
Copaxone
| | |
|
MS 47/11
|
F/48
|
5
|
RR
|
5 yr
|
N
|
Rebif
| | |
- Key: mo months, yr years, NK not known.
